$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

$rnac Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000145368716000011 Filed on November 10, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$2.930M	$1.048M	$1.607M
YoY Change	37.3%	-34.79%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.760M	$2.500M	$2.200M
YoY Change	183.74%	13.64%
% of Gross Profit
Research & Development	$11.03M	$6.021M	$5.483M
YoY Change	52.98%	9.81%
% of Gross Profit
Depreciation & Amortization	$250.0K	$100.0K	$200.0K
YoY Change	47.06%	-50.0%
% of Gross Profit
Operating Expenses	$16.79M	$8.516M	$7.678M
YoY Change	81.69%	10.91%
Operating Profit		-$7.468M	-$6.071M
YoY Change		23.01%
Interest Expense	-$310.0K	$311.0K	$334.0K
YoY Change	-234.78%	-6.89%
% of Operating Profit
Other Income/Expense, Net	$80.00K	$4.000K	-$13.00K
YoY Change	300.0%	-130.77%
Pretax Income	-$14.08M	-$7.730M	-$5.730M
YoY Change	105.55%	34.9%
Income Tax
% Of Pretax Income
Net Earnings	-$14.08M	-$7.728M	-$5.725M
YoY Change	105.62%	34.99%
Net Earnings / Revenue	-480.65%	-737.4%	-356.25%
Basic Earnings Per Share
Diluted Earnings Per Share	-$768.1K	-$426.8K	-$2.653M
COMMON SHARES
Basic Shares Outstanding	18.19M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$84.10M	$79.30M
YoY Change
Cash & Equivalents	$58.66M	$59.49M	$37.51M
Short-Term Investments	$25.50M	$19.80M
Other Short-Term Assets	$2.500M	$3.600M
YoY Change
Inventory
Prepaid Expenses
Receivables	$215.0K	$483.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$86.82M	$83.40M
YoY Change	123.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.047M	$2.066M
YoY Change	0.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$122.0K	$0.00
YoY Change	-92.21%
Total Long-Term Assets	$2.485M	$2.382M
YoY Change	-36.46%
TOTAL ASSETS
Total Short-Term Assets	$86.82M	$83.40M
Total Long-Term Assets	$2.485M	$2.382M
Total Assets	$89.30M	$85.78M
YoY Change	108.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.882M	$1.040M
YoY Change	78.16%
Accrued Expenses	$3.921M	$2.434M
YoY Change	16.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.100M	$2.900M
YoY Change
Total Short-Term Liabilities	$13.71M	$7.690M
YoY Change	88.01%
LONG-TERM LIABILITIES
Long-Term Debt	$8.000M	$9.100M
YoY Change
Other Long-Term Liabilities	$0.00	$0.00
YoY Change	-100.0%
Total Long-Term Liabilities	$0.00	$0.00
YoY Change	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.71M	$7.690M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$34.34M	$20.34M
YoY Change	57.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$151.6M	-$137.5M
YoY Change	35.96%
Common Stock	$1.000K	$1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$54.96M	$65.44M
YoY Change
Total Liabilities & Shareholders Equity	$89.30M	$85.78M
YoY Change	108.53%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$14.08M	-$7.728M	-$5.725M
YoY Change	105.62%	34.99%
Depreciation, Depletion And Amortization	$250.0K	$100.0K	$200.0K
YoY Change	47.06%	-50.0%
Cash From Operating Activities	$1.560M	-$5.470M	-$5.610M
YoY Change	-120.42%	-2.5%
INVESTING ACTIVITIES
Capital Expenditures	-$110.0K	-$280.0K	-$480.0K
YoY Change	-15.38%	-41.67%
Acquisitions
YoY Change
Other Investing Activities	-$5.090M	-$19.94M	-$740.0K
YoY Change	83.09%	2594.59%
Cash From Investing Activities	-$5.200M	-$20.21M	-$1.220M
YoY Change	78.69%	1556.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.790M	2.360M	31.98M
YoY Change	-50.97%	-92.62%
NET CHANGE
Cash From Operating Activities	1.560M	-5.470M	-5.610M
Cash From Investing Activities	-5.200M	-20.21M	-1.220M
Cash From Financing Activities	2.790M	2.360M	31.98M
Net Change In Cash	-850.0K	-23.32M	25.15M
YoY Change	-82.51%	-192.72%
FREE CASH FLOW
Cash From Operating Activities	$1.560M	-$5.470M	-$5.610M
Capital Expenditures	-$110.0K	-$280.0K	-$480.0K
Free Cash Flow	$1.670M	-$5.190M	-$5.130M
YoY Change	-122.24%	1.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001453687
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18190180	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	SELECTA BIOSCIENCES INC
CY2015Q4	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	219000	USD
CY2016Q3	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	184000	USD
CY2015Q4	selb	Accrued Rent And Lease Incentive Payable Current AccruedRentAndLeaseIncentivePayableCurrent	405000	USD
CY2016Q3	selb	Accrued Rent And Lease Incentive Payable Current AccruedRentAndLeaseIncentivePayableCurrent	12000	USD
CY2015Q4	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	1649000	USD
CY2016Q3	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	662000	USD
CY2015Q3	selb	Class Of Warrants Or Rights Term ClassOfWarrantsOrRightsTerm	P3Y
CY2015Q3	selb	Class Of Warrants Or Rights Term ClassOfWarrantsOrRightsTerm	P3Y
CY2015Q4	selb	Contingently Repayable Grant Funding Current ContingentlyRepayableGrantFundingCurrent	420000	USD
CY2016Q3	selb	Contingently Repayable Grant Funding Current ContingentlyRepayableGrantFundingCurrent	262000	USD
CY2016Q2	selb	Convertible Preferred Stock Warrants Fair Value Of Underlying Common Shares ConvertiblePreferredStockWarrantsFairValueOfUnderlyingCommonShares	14.00
CY2015Q4	selb	Deferred Rent And Lease Incentive Liability DeferredRentAndLeaseIncentiveLiability	500000	USD
CY2016Q3	selb	Deferred Rent And Lease Incentive Liability DeferredRentAndLeaseIncentiveLiability	200000	USD
	selb	Increase Decrease In Contingently Repayable Grant Funding IncreaseDecreaseInContingentlyRepayableGrantFunding	-446000	USD
	selb	Increase Decrease In Contingently Repayable Grant Funding IncreaseDecreaseInContingentlyRepayableGrantFunding	-207000	USD
CY2015	selb	Investments Maturity Period InvestmentsMaturityPeriod	P106D
	selb	Noncash Or Partial Noncash Reclassification Of Deferred Ipo Costs From Non Current Assets To Additional Paid In Capital NoncashOrPartialNoncashReclassificationOfDeferredIpoCostsFromNonCurrentAssetsToAdditionalPaidInCapital	0	USD
	selb	Noncash Or Partial Noncash Reclassification Of Deferred Ipo Costs From Non Current Assets To Additional Paid In Capital NoncashOrPartialNoncashReclassificationOfDeferredIpoCostsFromNonCurrentAssetsToAdditionalPaidInCapital	4369000	USD
	selb	Proceeds From Vesting Of Restricted Stock ProceedsFromVestingOfRestrictedStock	0	USD
	selb	Proceeds From Vesting Of Restricted Stock ProceedsFromVestingOfRestrictedStock	16000	USD
	selb	Stock Issued During The Period Value Warrants Exercised StockIssuedDuringThePeriodValueWarrantsExercised	0	USD
	selb	Stock Vested During Period Value Restricted Common Stock StockVestedDuringPeriodValueRestrictedCommonStock	16000	USD
	selb	Stockholders Equity Accretion To Redemption Value StockholdersEquityAccretionToRedemptionValue	4566000	USD
CY2016Q2	selb	Temporary Equity Conversion Of Convertible Stock Shares TemporaryEquityConversionOfConvertibleStockShares	10126118	shares
CY2016Q3	selb	Votes Per Shareof Common Stock VotesPerShareofCommonStock	1
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2179000	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1040000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	824000	USD
CY2016Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	483000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-113000	USD
CY2015Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	669000	USD
CY2016Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	519000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3378000	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2434000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	213000	USD
CY2016Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	59000	USD
CY2015Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	0	USD
CY2016Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	297000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2927000	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3504000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4986000	USD
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4554000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1000	USD
CY2016Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	207489000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1281000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	252000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	869000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	633000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1281000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9055165	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2254090	shares
CY2015Q4	us-gaap	Assets Assets	42824000	USD
CY2016Q3	us-gaap	Assets Assets	85779000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	38913000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	83397000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	3516000	USD
CY2016Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	19788000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2016Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	23000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	3516000	USD
CY2016Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	19804000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	3516000	USD
CY2016Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	19804000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	3516000	USD
CY2016Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	19788000	USD
CY2016Q3	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	11	position
CY2016Q3	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	13	position
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	11000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	31000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16592000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37514000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32337000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59488000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	20922000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	27151000	USD
CY2015Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	17.55
CY2015Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	80813	shares
CY2015Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	80813	shares
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12826886	shares
CY2016Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3037584	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	62164377	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2180976	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18190180	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2173399	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18188313	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6525000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19088000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7697000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21695000	USD
CY2016Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	10126118	shares
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	7288000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	105000	USD
CY2016Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	234000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1313000	USD
CY2016Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1041000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2295000	USD
CY2016Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3348000	USD
CY2015Q3	us-gaap	Depreciation Depreciation	200000	USD
	us-gaap	Depreciation Depreciation	866000	USD
	us-gaap	Depreciation Depreciation	900000	USD
CY2016Q3	us-gaap	Depreciation Depreciation	100000	USD
	us-gaap	Depreciation Depreciation	545000	USD
	us-gaap	Depreciation Depreciation	500000	USD
	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.50
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-10.86
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.39
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-705000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	419000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-17000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	12000	USD
CY2015Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	668000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	616000	USD
CY2016Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-51000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-429000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2195000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6305000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2495000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7294000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	363000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-35000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-112000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-341000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	870000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-763000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-34000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	586000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	608000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	85779000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7290000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7690000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1668000	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-1388000	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-507000	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	334000	USD
	us-gaap	Interest Expense InterestExpense	843000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	311000	USD
	us-gaap	Interest Expense InterestExpense	931000	USD
	us-gaap	Interest Paid InterestPaid	418000	USD
	us-gaap	Interest Paid InterestPaid	729000	USD
CY2015Q3	us-gaap	Investment Income Net InvestmentIncomeNet	25000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	149000	USD
CY2016Q3	us-gaap	Investment Income Net InvestmentIncomeNet	98000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	121000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	21835000	USD
CY2016Q3	us-gaap	Liabilities Liabilities	20336000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42824000	USD
CY2015Q4	us-gaap	Loans Payable Current LoansPayableCurrent	0	USD
CY2016Q3	us-gaap	Loans Payable Current LoansPayableCurrent	2913000	USD
CY2015Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	11855000	USD
CY2016Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	9064000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	16000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	38220000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	64867000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1770000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-16896000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-14823000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-21239000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-5725000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18325000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-7728000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22127000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7561000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23284000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7728000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26693000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	7678000	USD
	us-gaap	Operating Expenses OperatingExpenses	22074000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	8516000	USD
	us-gaap	Operating Expenses OperatingExpenses	25963000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6071000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18197000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7468000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20810000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	5376000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	335000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1330000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1291000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1244000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	1176000	USD
CY2015Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1000000	USD
CY2016Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1100000	USD
CY2015	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	200000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	223000	USD
CY2016Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	701000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1566000	USD
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-800000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-763000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	15000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	416000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	16000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	16000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	290000	USD
CY2016Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-50000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-78000	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	139000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	176000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4068000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1031000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	478000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	739000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	23318000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	6900000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	78000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	48000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4956000	USD
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1494000	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3303000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	7092000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	68871000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	32669000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	USD
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5570000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2029000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2066000	USD
CY2015Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2016Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1619000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5483000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15769000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6021000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18669000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	133000	USD
CY2016Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	335000	USD
CY2015Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	316000	USD
CY2016Q3	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	316000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111508000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111500000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-137500000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-137493000	USD
CY2015Q3	us-gaap	Revenues Revenues	1607000	USD
	us-gaap	Revenues Revenues	3877000	USD
CY2016Q3	us-gaap	Revenues Revenues	1048000	USD
	us-gaap	Revenues Revenues	5153000	USD
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	4125000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	4566000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	64501000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	48000	USD
CY2016Q3	us-gaap	Short Term Investments ShortTermInvestments	19788000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	142048000	USD
CY2015Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	137482000	USD
CY2016Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2015Q3	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	1836000	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	4959000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-116493000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	65443000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	4959000	USD
CY2016Q3	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	4566000	USD
CY2016Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2159658	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2144731	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18108014	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7881625	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations of Credit Risk and Off‑Balance Sheet Risk</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and accounts receivable. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company’s deposits are financially credit worthy and, accordingly, minimal risk exists with respect to those balances. Generally, these deposits may be redeemed upon demand and therefore bear minimal interest rate risk. As an integral part of operating its Russian subsidiary, the Company also maintains cash in Russian bank accounts in denominations of both rubles and U.S. dollars.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s management considers many factors in selecting appropriate financial accounting policies and controls, and bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: revenue recognition, the fair value of common stock and other equity instruments, accounting for stock-based compensation, income taxes, collectability of accounts receivable, useful lives of long-lived assets, accrued expenses, and accounting for project development. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s management made significant estimates and assumptions in determining the fair value of its common stock for those periods reported prior to the completion of the IPO. The Company utilized various valuation methodologies in accordance with the framework of the 2004 American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. Each valuation methodology included estimates and assumptions that require the Company’s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time and the likelihood of achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date.</font></div></div>

Files In Submission

Name	View Source	Status
0001453687-16-000011-index-headers.html	Edgar Link	pending
0001453687-16-000011-index.html	Edgar Link	pending
0001453687-16-000011.txt	Edgar Link	pending
0001453687-16-000011-xbrl.zip	Edgar Link	pending
exhibit31193016.htm	Edgar Link	pending
exhibit32193016.htm	Edgar Link	pending
exhibit32293016.htm	Edgar Link	pending
exhibt31293016.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
selb-20160930.xml	Edgar Link	completed
selb-20160930.xsd	Edgar Link	pending
selb-20160930_cal.xml	Edgar Link	unprocessable
selb-20160930_def.xml	Edgar Link	unprocessable
selb-20160930_lab.xml	Edgar Link	unprocessable
selb-20160930_pre.xml	Edgar Link	unprocessable
selectabiosciences10-q93016.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

2016 Q4 Form 10-Q Financial Statement

#000145368716000011 Filed on November 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC Cartesian Therapeutics, Inc. Stock $rnac

2016 Q4 Form 10-Q Financial Statement

#000145368716000011 Filed on November 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac